, Volume 27, Issue 1, pp 57-67
Date: 03 Sep 2008

Transfusion associated microchimerism: a heretofore little recognized complication following transfusion

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Potent antiplatelet and antithrombotic agents have significantly reduced mortality in the setting of acute coronary syndromes and percutaneous coronary intervention. However these agents are associated with increased bleeding which is in turn associated with adverse clinical outcomes. In many centers, transfusion is often used to correct for blood loss. Blood transfusion in the setting of acute coronary syndrome has been associated with adverse clinical outcomes including increased mortality. Transfusion associated microchimerism (TA-MC) is a newly recognized complication of blood transfusion. There is engraftment of the donor’s hematopoietic stem cells in patients who then develop microchimerism. This article discusses the association of bleeding/blood transfusion with adverse outcomes and the potential role of TA-MC in clinical outcomes.

The authors have received research grant support and consulting fees in the past from Eli Lilly, Schering Plough, and Astra Zeneca.
Dr. Vijayalakshmi Kunadian has received unrestricted educational research grant support from South Cleveland Heart Fund, The James Cook University Hospital, Middlesbrough, United Kingdom.